BNP Paribas Arbitrage SA increased its holdings in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 8.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 75,084 shares of the specialty pharmaceutical company’s stock after buying an additional 6,159 shares during the period. BNP Paribas Arbitrage SA owned about 0.21% of AMAG Pharmaceuticals worth $1,382,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. State of Alaska Department of Revenue boosted its holdings in shares of AMAG Pharmaceuticals by 81.3% in the 2nd quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock valued at $126,000 after buying an additional 3,081 shares during the period. Advisors Asset Management Inc. boosted its holdings in shares of AMAG Pharmaceuticals by 259.9% in the 1st quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock valued at $156,000 after buying an additional 5,005 shares during the period. Mason Street Advisors LLC boosted its holdings in shares of AMAG Pharmaceuticals by 7.4% in the 1st quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $181,000 after buying an additional 554 shares during the period. Municipal Employees Retirement System of Michigan boosted its holdings in shares of AMAG Pharmaceuticals by 6.6% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 510 shares during the period. Finally, Sei Investments Co. boosted its holdings in shares of AMAG Pharmaceuticals by 0.7% in the 1st quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock valued at $188,000 after buying an additional 54 shares during the period.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of the company’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $98,760.00. Following the transaction, the senior vice president now directly owns 28,336 shares in the company, valued at approximately $566,720. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 3.80% of the company’s stock.

Several research analysts have recently commented on AMAG shares. ValuEngine lowered shares of AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Barclays PLC reiterated a “hold” rating and issued a $25.00 price objective on shares of AMAG Pharmaceuticals in a research report on Monday, May 15th. Cantor Fitzgerald reiterated a “hold” rating and issued a $23.00 price objective on shares of AMAG Pharmaceuticals in a research report on Monday, June 26th. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Finally, Citigroup Inc. cut their price objective on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating on the stock in a research report on Friday, July 7th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $28.09.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/05/bnp-paribas-arbitrage-sa-boosts-stake-in-amag-pharmaceuticals-inc-amag.html.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) opened at 17.60 on Tuesday. AMAG Pharmaceuticals, Inc. has a 52-week low of $16.00 and a 52-week high of $36.83. The company’s market capitalization is $621.07 million. The firm’s 50 day moving average is $18.29 and its 200-day moving average is $20.17.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The company had revenue of $158.39 million for the quarter, compared to the consensus estimate of $158.83 million. During the same period in the prior year, the company posted $1.45 EPS. The company’s revenue was up 24.3% compared to the same quarter last year. Equities research analysts anticipate that AMAG Pharmaceuticals, Inc. will post ($1.38) earnings per share for the current fiscal year.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.